BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

BACKGROUND: Colorectal cancer (CRC) is a heterogeneous disease with a complex biology and a wide number of altered genes such as BRAF, KRAS and PIK3CA. Advances with new-targeted therapies have been achieved and available treating options have prolonged patient’s survival. However, BRAF-mutated CRC...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Cancer
Glavni autori: Miele, Evelina, Abballe, Luana, Spinelli, Gian Paolo, Besharat, Zein Mersini, Catanzaro, Giuseppina, Chiacchiarini, Martina, Vacca, Alessandra, Po, Agnese, Capalbo, Carlo, Ferretti, Elisabetta
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2020
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027203/
https://ncbi.nlm.nih.gov/pubmed/32066410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6586-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items